Takeda Pharmaceutical Company Limited http://www.takeda.com/ R&D News Takeda Pharmaceutical Company Limited http://www.takeda.com/ http://www.takeda.com/favicon.ico icon Anti-Prostate Cancer Agent Orteronel(TAK-700) Enters into Phase III Clinical Trials in Japan http://www.takeda.com/press/article_44988.html Osaka, Japan, Cambridge, Mass and Tokyo, Japan, January 27, 2012 – Takeda Pharmaceutical Company Limited (“Takeda”) and Millennium: The Takeda Oncology Company (“Millennium”) today announced that Takeda Bio Development Center Limited (“Takeda Bio”) has initiated enrollment of patients in Japan for the two ongoing global Phase III clinical trials for the anti-prostate cancer investigational agent, orteronel(TAK-700). 2012-01-27T15:00:00+09:00 FDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications http://www.takeda.com/press/article_44980.html CAMBRIDGE, Mass., January 23, 2012–Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE® (bortezomib), which updates the label to include the subcutaneous method of administration in all approved indications: multiple myeloma and mantle cell lymphoma after at least one prior therapy. 2012-01-24T09:00:00+09:00 New Drug Application Approval for AZILVA® in Japan, a Treatment of Hypertension http://www.takeda.com/press/article_44965.html Osaka, Japan, January 18 2012 --- Takeda Pharmaceutical Company Limited (“Takeda”) announced today that its New Drug Application (NDA) for its investigational compound AZILVA (generic name: azilsartan) for the treatment of hypertension has been approved by the Ministry of Health, Labour and Welfare. Discovered by Takeda, azilsartan is an angiotensin II receptor blocker (“ARB”) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone. Azilva is a once-daily, orally administered single tablet, and the approved doses are 20 mg and 40 mg. 2012-01-18T15:00:00+09:00 Establishment of Joint Research Chair by Takeda and Osaka UniversityDevelopment of platform for practical application and commercialization of nano-particle vaccines http://www.takeda.com/press/article_44852.html Osaka, Japan, January 6, 2012 – Osaka University and Takeda Pharmaceutical Company Limited (“Takeda”) announced today their agreement on the establishment of a Joint Research Chair for 3 years to develop a platform for the practical application and commercialization of vaccines using hydrophobic poly (γ-glutamic acid) (γ-PGA) nano-particles(A(*1 (“nano-particles”) as adjuvant(A(*2. 2012-01-06T15:00:00+09:00 FDA Approves EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension-First and only fixed-dose combination medication in the U.S. to combine an angiotensin II receptor blocker with the diuretic chlorthalidone- http://www.takeda.com/press/article_44059.html Deerfield, Ill., December 20, 2011, and Osaka, Japan, December 21, 2011 – Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., announced today that the U.S. Food and Drug Administration (FDA) approved EDARBYCLOR (azilsartan medoxomil and chlorthalidone) for the treatment of hypertension to lower blood pressure in adults. EDARBYCLOR is the only fixed-dose therapy in the U.S. to combine an angiotensin II receptor blocker (ARB) with the diuretic chlorthalidone in a once-daily, single tablet. The recommended starting dose of EDARBYCLOR is 40/12.5 mg and the maximum dose is 40/25 mg. 2011-12-21T10:00:00+09:00